Back to Search
Start Over
S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes.
- Source :
-
Frontiers in immunology [Front Immunol] 2021 Dec 23; Vol. 12, pp. 803090. Date of Electronic Publication: 2021 Dec 23 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Robust induction of cancer-antigen-specific CD8 <superscript>+</superscript> T cells is essential for the success of cancer peptide vaccines, which are composed of a peptide derived from a cancer-specific antigen and an immune-potentiating adjuvant, such as a Toll-like receptor (TLR) agonist. Efficient delivery of a vaccine antigen and an adjuvant to antigen-presenting cells in the draining lymph nodes (LNs) holds key to maximize vaccine efficacy. Here, we developed S-540956, a novel TLR9-agonistic adjuvant consisting of B-type CpG ODN2006 (also known as CpG7909), annealed to its complementary sequence oligodeoxynucleotide (ODN) conjugated to a lipid; it could target both a cancer peptide antigen and a CpG-adjuvant in the draining LNs. S-540956 accumulation in the draining LNs and activation of plasmacytoid dendritic cells (pDCs) were significantly higher than that of ODN2006. Mechanistic analysis revealed that S-540956 enhanced the induction of MHC class I peptide-specific CD8 <superscript>+</superscript> T cell responses via TLR9 in a CD4 <superscript>+</superscript> T cell-independent manner. In mice, the therapeutic effect of S-540956-adjuvanted with a human papillomavirus (HPV)-E7 peptide vaccine against HPV-E7-expressing TC-1 tumors was significantly better than that of an ODN2006-adjuvanted vaccine. Our findings demonstrate a novel adjuvant discovery with the complementary strand conjugated to a lipid, which enabled draining LN targeting and increased ODN2006 accumulation in draining LNs, thereby enhancing the adjuvant effect. Our findings imply that S-540956 is a promising adjuvant for cancer peptide vaccines and has a high potential for applications in various vaccines, including recombinant protein vaccines.<br />Competing Interests: TN, TT, MO, ST, TK, YI, TI, AK, KK, and MN are employees of Shionogi & Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Shionogi & Co., Ltd. The funder had the following involvement in the study: study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.<br /> (Copyright © 2021 Nakagawa, Tanino, Onishi, Tofukuji, Kanazawa, Ishioka, Itoh, Kugimiya, Katayama, Yamamoto, Nagira and Ishii.)
- Subjects :
- Adjuvants, Vaccine chemistry
Animals
Cell Differentiation
DNA chemistry
Female
Humans
Immunization
Lymphocyte Activation
Mice
Mice, Inbred C57BL
Neoplasms, Experimental
Oligodeoxyribonucleotides chemistry
Surface-Active Agents chemistry
Toll-Like Receptor 9 agonists
Toll-Like Receptor 9 genetics
Vaccines, Subunit
Adjuvants, Vaccine therapeutic use
CD8-Positive T-Lymphocytes immunology
Cancer Vaccines immunology
Dendritic Cells immunology
Lung Neoplasms immunology
Oligodeoxyribonucleotides administration & dosage
Papillomavirus E7 Proteins immunology
Sentinel Lymph Node immunology
Toll-Like Receptor 9 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 35003132
- Full Text :
- https://doi.org/10.3389/fimmu.2021.803090